A nurse is assessing a client who has heart failure and is taking digoxin. Which of the following findings should the nurse identify as an early indication of medication toxicity?

Choice A Reason:
INR (International Normalized Ratio) is incorrect. INR is a measurement used to monitor the effects of anticoagulants like warfarin. It assesses the blood's ability to clot. Filgrastim does not directly affect INR levels, so monitoring INR would not provide information about the effectiveness of filgrastim in stimulating white blood cell production.
Choice B Reason:
BUN (Blood Urea Nitrogen) is incorrect. BUN levels primarily indicate kidney function and hydration status. They are not directly influenced by filgrastim treatment. Monitoring BUN is essential for assessing kidney function but does not reflect the effectiveness of filgrastim therapy in increasing white blood cell counts.
Choice C Reason:
WBC count is correct. Filgrastim is a medication that stimulates the production of white blood cells (WBCs), particularly neutrophils. Therefore, the key laboratory value to monitor for assessing the effectiveness of filgrastim therapy is the WBC count. An increase in the WBC count, particularly in the neutrophil count, signifies the intended therapeutic effect of filgrastim in boosting the immune system's response by increasing the production of these infection-fighting cells.
Choice D Reason:
Potassium level is incorrect. Potassium levels are crucial for heart and muscle function. While certain medications might affect potassium levels, filgrastim's primary action is on stimulating white blood cell production and does not directly impact potassium levels. Monitoring potassium levels is essential for overall health but does not specifically indicate the effectiveness of filgrastim treatment.

Choice A Reason:
Regular insulin is incorrect. Regular insulin is a short-acting insulin used for managing diabetes, particularly for controlling blood sugar levels during meals. However, it's not typically the initial medication introduced in the management of metabolic syndrome with an HbA1c of 6.5%. Insulin therapy is generally considered when other medications or lifestyle changes aren't effective in controlling blood sugar levels.
Choice B Reason:
Exenatide is incorrect. Exenatide is a GLP-1 receptor agonist, used to manage type 2 diabetes. While it's effective in controlling blood sugar levels, it's often considered after initial treatments like metformin, especially in newly diagnosed cases or those with moderately elevated HbA1c levels.
Choice C Reason:
Insulin glargine is incorrect. Insulin glargine is a long-acting insulin used in diabetes management, providing a steady level of insulin throughout the day. Like regular insulin, insulin glargine is typically considered later in the treatment plan and is not usually the first medication introduced in cases of new metabolic syndrome diagnoses with moderately elevated HbA1c levels.
Choice D Reason:
Considering the client's new diagnosis and moderately elevated HbA1c level, educating about metformin aligns with the typical first-line approach in managing blood sugar levels and metabolic syndrome in this scenario.